Kaitlyn D’Onofrio

DocwireNews

A dose-optimization trial compared efficacy and toxicity outcomes for two daily dose regimens of duvelisib in patients with <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/anti-cd19-anti-bcma-car-t-cells/">relapsed or refractory</a> (R/R) peripheral T-cell lymphoma (PTCL). The <a href="https://ash.confex.com/ash/2019/webprogram/Paper121401.html">study</a> was presented at the <a href="https://www.docwirenews.com/conference-coverage/soho/">American Society of Hematology Annual Meeting</a>.Lead study author Steven Horwitz, MD, answered some questions about the study in an interview with DocWire News.DocWire News: What prompted you to undertake this study?Dr. Horwitz: We have conducted early studies suggesting quite good activity of duvelisib as a single agent in a range of subtypes of T-cell lymphoma. The Primo study, which will include over 100 patients will be sufficiently powered to give a much more precise estimate of the activity in peripheral t cell lymphomas. Based on the size of the study, we are hopeful that we might also gain some insight into whether there are differences in subtype specific activity. &nbsp;However, prior to initiating the main cohort we needed to first try to identify an optimal dose. That &ldquo;dose optimization cohort&rdquo; is the subject of our presentation here.DW: What are the key takeaways from the study?Dr. Horwitz: Relapsed or refractory Peripheral T-Cell Lymphoma (R/R PTCL) remains a disease of significant unmet medical need.Duvelisib is an oral dual inhibitor of PI3K-&delta; and PI3K-&gamma; approved for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies, relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies, and is being developed for the treatment of additional hematologic malignancies including R/R PTCL.The PRIMO study is an ongoing, multi-center, open-label, registration-directed Phase 2 study evaluating duvelisib in patients with R/R PTCL that is expected to enroll approximately 120 patients. The study includes both a dose optimization phase and an expansion phase.Results from a Phase 1 study suggest duvelisib monotherapy has activity in R/R PTCL. The objective of the Phase 2 PRIMO study is to first identify the optimal dose of duvelisib and then examine its efficacy, safety, and tolerability at the optimal dose.In the dose optimization portion of the study, patients were randomized to receive duvelisib 25mg twice daily (cohort 1) or duvelisib 75mg twice daily continuously (cohort 2) until disease progression or unacceptable toxicity. The primary endpoint of the study was investigator-assessed overall response rate (ORR), and secondary endpoints included duration of response (DOR) and safety.The investigator-assessed ORR in the ITT population was 35% in cohort 1 (n=20) and 54% in cohort 2 (n=13), with a complete response rate (CR) of 25% and 31% in cohort 1 and cohort 2, respectively. The ORR assessed by a blinded independent review, also in the ITT population, was 40% and 62% for cohort 1 and cohort 2, respectively. Nearly all of the responses were identified on first assessment. The most common (&ge;4 patients) Grade &ge;3 adverse events (AEs) in all patients receiving duvelisib were neutropenia, thrombocytopenia, diarrhea, rash/maculopapular, lymphocytopenia, pneumonia and sepsis. Serious AEs occurring in &gt;2 patients were colitis, diarrhea, abdominal pain, pyrexia, sepsis, pneumonia, hyponatremia, rash/maculopapular, dyspnea, and respiratory failure. Overall, 12% of patients receiving duvelisib discontinued due to an AE.It appears that while there were responses, including complete responses at both the 25mg twice daily and duvelisib 75mg twice daily cohorts, more patients had early progression in the 25mg twice daily cohort. The analysis of drug levels (pk) in cycle 1 suggest that higher levels of drug in the blood seen in the 75mg twice daily may correlate with better early disease control. Due to this finding, &nbsp;patients in the rest of the study will start with 75 mg twice daily dosing but then have their dose reduced to hopefully minimize any long-term side effects.DW: Did any of the study&rsquo;s findings surprise you? Dr. Horwitz: No significant surprises.&nbsp; The overall responses and side effects are quite similar to what we saw in earlier studies. The only mild surprise was in earlier small studies we had not seen rapid early progression at the 25 mg twice daily dosing.DW: What limitations did the study have?Dr. Horwitz: The dose optimization phase included a relatively small number of patients.DW: Do you have any future research plans pertaining to this area?Dr. Horwitz: The expansion phase of this registration-directed study is currently underway in the United States and is opening in Germany, UK, Italy, and Japan.

Jordana Jampel

Successful HIV Viral Suppression With At-Home Administration

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Latest News

Two Duvelisib Doses Effective in Relapsed/Refractory Peripheral T-cell Lymphoma

Oncology

A dose-optimization trial compared efficacy and toxicity outcomes for two daily dose regimens of duvelisib in patients with relapsed or refractory (R/R) peripheral T-cell ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe